Merck & Co., Inc. $MRK Shares Acquired by Diamant Asset Management Inc.

Key Points

• Diamant Asset Management dramatically increased its Merck stake in Q1, boosting holdings by 12,130.3% to 2.07 million shares valued at about $248.8 million.
• Merck received several positive regulatory and pipeline updates, including FDA approval for Keytruda/Keytruda Qlex with Trodelvy in advanced triple-negative breast cancer and EU approval for Keytruda plus Padcev in bladder cancer.
• The company reported better-than-expected quarterly results, with EPS and revenue both topping estimates, and it also announced a quarterly dividend of $0.85 per share payable on July 8.

Diamant Asset Management Inc. boosted its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 12,130.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,068,387 shares of the company's stock after buying an additional 2,051,475 shares during the period. Merck & Co., Inc. accounts for 0.8% of Diamant Asset Management Inc.'s portfolio, making the stock its 23rd biggest holding. Diamant Asset Management Inc. owned about 0.08% of Merck & Co., Inc. worth $248,806,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new stake in Merck & Co., Inc. in the third quarter worth approximately $31,000. Finally, High Note Wealth LLC lifted its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRK. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. Royal Bank Of Canada reissued an "outperform" rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wells Fargo & Company decreased their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating for the company in a research note on Friday, May 1st. Citigroup assumed coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 target price on the stock. Finally, UBS Group lifted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $128.72.

Merck & Co., Inc. Trading Up 2.3%

Merck & Co., Inc. stock opened at $128.35 on Friday. The firm has a market cap of $316.99 billion, a price-to-earnings ratio of 36.15, a price-to-earnings-growth ratio of 2.89 and a beta of 0.21. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $128.78. The firm's 50 day moving average price is $116.08 and its two-hundred day moving average price is $114.33. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.'s payout ratio is 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.